BioLife Solutions Updates 2025 Revenue Guidance to $100-103mln, Reflecting 22-25% YoY Growth
PorAinvest
jueves, 7 de agosto de 2025, 5:08 pm ET1 min de lectura
BLFS--
The revised guidance reflects strong performance in the second quarter of 2025, where cell processing revenue reached $23.0 million, up 28% year-over-year. This growth was driven by the company's biopreservation media (BPM) franchise, which saw continued strength across both direct and distributor channels. The company's media is embedded in 16 approved therapies and supports over 250 ongoing commercial trials, including over 30 in Phase III [1].
BioLife Solutions also reported a GAAP gross margin of 62% and a non-GAAP adjusted gross margin of 65% for the second quarter. The company expects gross margins to remain in the low 60% range (GAAP) and mid-60% range (non-GAAP) for the full year 2025. Additionally, the company aims to reduce its net loss and expand adjusted EBITDA margin compared to 2024 [1].
The company's earnings call and webcast are scheduled for today at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the webcast via the BioLife Solutions Investor Relations page or by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers [1].
References:
[1] https://www.prnewswire.com/news-releases/biolife-solutions-reports-second-quarter-2025-financial-results-302524721.html
BioLife Solutions, Inc. revised its earnings guidance for 2025, expecting revenue to be between $100.0 million and $103.0 million, a 22% to 25% increase from 2024. The guidance reflects a year-over-year growth of 24% to 26% for the Cell Processing platform revenue and a year-over-year growth of 3% to 15% for evo and Thaw platform revenue.
BioLife Solutions, Inc. (Nasdaq: BLFS) has revised its financial projections for 2025, forecasting revenue to range between $100.0 million and $103.0 million. This represents a 22% to 25% increase from the prior year, with a focus on growth across its Cell Processing and evo and Thaw platforms. The company expects cell processing revenue to grow by 24% to 26%, while evo and Thaw platform revenue is anticipated to increase by 3% to 15% [1].The revised guidance reflects strong performance in the second quarter of 2025, where cell processing revenue reached $23.0 million, up 28% year-over-year. This growth was driven by the company's biopreservation media (BPM) franchise, which saw continued strength across both direct and distributor channels. The company's media is embedded in 16 approved therapies and supports over 250 ongoing commercial trials, including over 30 in Phase III [1].
BioLife Solutions also reported a GAAP gross margin of 62% and a non-GAAP adjusted gross margin of 65% for the second quarter. The company expects gross margins to remain in the low 60% range (GAAP) and mid-60% range (non-GAAP) for the full year 2025. Additionally, the company aims to reduce its net loss and expand adjusted EBITDA margin compared to 2024 [1].
The company's earnings call and webcast are scheduled for today at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the webcast via the BioLife Solutions Investor Relations page or by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers [1].
References:
[1] https://www.prnewswire.com/news-releases/biolife-solutions-reports-second-quarter-2025-financial-results-302524721.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios